Ocata Therapeutics Inc  

(Public, NASDAQ:OCAT)   Watch this stock  
6.16
+0.03 (0.49%)
Mar 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.13 - 6.22
52 week 4.95 - 12.73
Open 6.16
Vol / Avg. 155,369.00/202,772.00
Mkt cap 214.81M
P/E     -
Div/yield     -
EPS -1.16
Shares 35.04M
Beta 1.07
Inst. own 0%
Mar 3, 2015
Ocata Therapeutics Inc at Cowen Health Care Conference
Feb 9, 2015
Ocata Therapeutics Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -17290.96% -22009.72%
Operating margin -17326.50% -22249.30%
EBITD margin - -13499.45%
Return on average assets -365.35% -720.53%
Return on average equity - -
Employees 37 -
CDP Score - -

Address

33 Locke Dr
MARLBOROUGH, MA 01752-1167
United States - Map
+1-508-7561212 (Phone)
+1-508-2292333 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc. is a biotechnology company, engaged in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The Company is actively conducting clinical trials for treating dry age-related macular degeneration and Stargardt�s macular degeneration, in addition to several clinical and preclinical programs for other ocular therapies. It also has a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The Company�s intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy research programs.

Officers and directors

Michael T. Heffernan Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Paul K. Wotton Ph.D. President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Edward H. Myles CPA Chief Financial Officer, Executive Vice President - Corporate Development
Age: 42
Bio & Compensation  - Reuters
Eddy Anglade M.D. Executive Vice President - Clinical Development
Age: 52
Bio & Compensation  - Reuters
LeRoux Jooste Senior Vice President - Business Development, Chief Commercial Officer
Bio & Compensation  - Reuters
Robert P. Lanza M.D. Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
John Heffernan Vice President - Manufacturing
Bio & Compensation  - Reuters
Robert S. Langer Independent Director
Age: 65
Bio & Compensation  - Reuters
Zohar Loshitzer Independent Director
Age: 56
Bio & Compensation  - Reuters
Gregory D. Perry Independent Director
Age: 54
Bio & Compensation  - Reuters